Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT03478163 Terminated - Clinical trials for Postpartum Hemorrhage

Antibiotics During Intrauterine Balloon Tamponade Placement

Start date: March 8, 2018
Phase: Phase 4
Study type: Interventional

The goal of this study is to identify whether antibiotics given at the time of placement of an intrauterine balloon tamponade (IBT) will result in reduction of the risk of endometritis. The investigators hypothesize that antibiotics given at the time of intrauterine balloon tamponade will reduce the likelihood of postpartum endometritis.

NCT ID: NCT03477708 Completed - Clinical trials for IVH- Intraventricular Hemorrhage

The Impact of Continuous Transcutaneous CO2 (TCCO2) Monitoring in Extremely Low Birth Weight (ELBW) Infants

Start date: January 1, 2018
Phase:
Study type: Observational

An observational study comparing outcomes of Extremely Low Birth Weight (ELBW) infants that were monitored with non-invasive Transcutaneous CO2 (TCCO2) monitor to infants that were not monitored by TCCO2 monitor.

NCT ID: NCT03476928 Terminated - Clinical trials for Uterine Fibroids and Heavy Menstrual Bleeding

A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

ASTEROID 8
Start date: March 30, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of vilaprisan in Japanese subjects with uterine fibroids and heavy menstrual bleeding (HMB).

NCT ID: NCT03471702 Terminated - Clinical trials for Subarachnoid Hemorrhage

A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)

Start date: February 28, 2018
Phase: N/A
Study type: Interventional

Aqueduct's Smart External Drain (SED) will be compared to the current gold standard for temporary CSF management in a hospital setting. - Evaluate the number of subjects requiring to be switched to a standard of care EVD - Evaluate subject transport while on the SED - Evaluate SED system control from initiation of SED through discharge of external drain system

NCT ID: NCT03469167 Completed - Clinical trials for Peptic Ulcer Bleeding

Study to Evaluate Efficacy and Safety of Wound Dressing Solution Containing EGF in Patients With Peptic Ulcers Bleeding

CEGP003
Start date: October 15, 2014
Phase: N/A
Study type: Interventional

This is a prospective, single-blinded, randomized study to evaluate the efficacy and safety of CEGP003 in patients with acute peptic ulcers bleeding, compared to endoscopic epinephrine injection therapy.

NCT ID: NCT03468738 Completed - Surgery Clinical Trials

Investigation of the Transfusion Practices in Surgical Patients in Turkey

CeKATU
Start date: April 2, 2018
Phase:
Study type: Observational

The aim of this study is to describe the transfusion practices in patients undergoing major surgery in Turkey. The transfusion rates of red blood cells (RBC), fresh frozen plasma (FFP) and platelets; the transfusion predictors and transfusion related patient outcomes are investigated.

NCT ID: NCT03464539 Completed - Clinical trials for Gastrointestinal Bleeding

Occult Obscure Gastrointestinal Bleeding

OGIB
Start date: February 1, 2017
Phase: N/A
Study type: Interventional

To test the activity of a polyglucosamine (PG) together with a Standard Management protocol (SM) on the occult and obscure gastrointestinal bleeding (OGIB) and the clinical symptoms in patients suffering from colonic diverticulitis (CD).

NCT ID: NCT03464513 Not yet recruiting - Clinical trials for Lower Gastrointestinal Bleeding

MSCT Angiography in Bleeding

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Lower gastrointestinal bleeding occurs distal to the ligament of treitz and may involve the small bowel, colon and rectum . Active lower gastrointestinal bleeding is a common, potentially life threatening medical presentation that can be challenging to localize and treat . There are many diseases that may cause lower gastrointestinal bleeding, including angiodysplasia, diverticulosis, benign or malignant bowel neoplasm, inflammatory bowel disease, ischemic bowel disease, and infectious bowel disease. Often, gastrointestinal bleeding will stop spontaneously, but in approximately 25% of patients, bleeding is massive or recurrent, requiring imaging localization and directed therapy.

NCT ID: NCT03464344 Active, not recruiting - Clinical trials for Cerebral Amyloid Angiopathy

Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.

CORELIA
Start date: October 12, 2018
Phase: N/A
Study type: Interventional

Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in the elderly with high risk of recurrence. The investigators aim to determine the relationship between cortical superficial siderosis (cSS), a MRI hemorrhagic marker of CAA and the risk of symptomatic ICH recurrence in a multicentric prospective cohort of patients with acute lobar ICH related to CAA. The investigators hypothesize that patients with cSS have an increased risk of recurrent symptomatic ICH relative to those without cSS.

NCT ID: NCT03463993 Completed - Clinical trials for Post Partum Hemorrhage

Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section

Start date: April 8, 2018
Phase: Phase 3
Study type: Interventional

Background Postpartum haemorrhage (PPH) is a major cause of maternal mortality worldwide accounting for 25% of maternal deaths. In Zimbabwe PPH is the second most common cause of death. Tranexamic acid (TXA) is widely used to reduce blood loss in elective surgery, bleeding trauma patients, and menorrhagia. The investigators seek to determine the efficacy of TXA in reducing PPH during and after elective caesarean section. Methods and Design The investigators intend to perform an open label randomized control study of 1,162 women who are undergoing elective caesarean section. The participants will be randomly selected to receive an intravenous infusion of TXA 10 minutes prior to skin incision or not to receive the intervention. Prophylactic oxytocin will be administered to all the women. The primary outcome will be incidence of PPH defined by blood loss equal to or more than 1,000ml calculated by determining the difference in haematocrit values taken prior to and 48 hours after caesarean section. Discussion In addition to prophylactic uterotonic administration, TXA is a complementary component acting on the haemostatic process that can be used in the third stage of labour to prevent PPH. It is a promising intervention that is cheap, easy to administer and would be easy to add to routine delivery protocols in hospitals. It would also help to conserve precious resources by reducing the need for blood products, and expensive surgical interventions to manage PPH. This large adequately powered randomized study seeks to determine the efficacy of TXA to validate its routine use at caesarean section to prevent PPH.